This content was produced with the help of AI and reviewed by STN editors before being published.
When someone is diagnosed with major depressive disorder and starts an antidepressant, the expectation is improvement. But for roughly 30–40% of people with depression, the first medication doesn't work adequately, and a significant number don't respond fully after two or more adequate trials. This is the clinical definition of treatment-resistant depression (TRD).
If that sounds familiar, you are not alone, and you are not without options.
Treatment-resistant depression is typically defined as depression that has not responded to at least two different antidepressant trials at adequate doses for an adequate duration (usually 6–8 weeks each). It does not mean your depression is untreatable. It means standard first-line approaches haven't been sufficient, and it's time to reassess.
Several factors can contribute to treatment resistance:
Your psychiatrist may add a second medication (such as lithium, an atypical antipsychotic like aripiprazole or quetiapine, or a different class of antidepressant) to boost the effect of your current treatment. This is often effective and worth trying before more intensive interventions.
A simple cheek swab can reveal how your genetic profile affects how you metabolize psychiatric medications. This helps your psychiatrist select medications that are better suited to your biology, rather than relying on trial and error.
TMS is an FDA-approved, non-invasive treatment that delivers focused magnetic pulses to the prefrontal cortex, the brain region responsible for mood regulation. Unlike medication, TMS works directly on the neural circuits involved in depression without systemic side effects.
TMS is performed in an outpatient setting, takes 20–40 minutes per session, and involves no anesthesia or downtime. Clinical trials show approximately 50–60% of TRD patients experience significant improvement, with about one-third achieving full remission.
Ketamine (intravenous) and its nasal spray form esketamine (Spravato) act on NMDA receptors rather than serotonin pathways, producing rapid antidepressant effects, sometimes within hours. Esketamine is FDA-approved for TRD and is administered in certified clinical settings.
Cognitive Behavioral Therapy (CBT), particularly when combined with medication, produces better long-term outcomes than medication alone. For TRD, specialized approaches like Cognitive Behavioral Analysis System of Psychotherapy (CBASP) may be worth exploring.
If your current treatment plan isn't working, the most important thing is to tell your provider rather than simply stop treatment. Abruptly discontinuing antidepressants can cause withdrawal symptoms and worsen depression.
At Segal Telepsychiatry Network, our psychiatrists specialize in complex and treatment-resistant depression. We offer comprehensive evaluations, pharmacogenomic testing, TMS therapy at our California location, and coordinated care that addresses all the factors driving your depression.
You don't have to keep cycling through medications hoping for different results. A more targeted approach is available.
Schedule a consultation to discuss your treatment history and explore what options may work for you.
Segal Telepsychiatry Network serves patients in California, Florida, and New York. No referral needed. We typically schedule within days.
Get Started Today
